TCGA-CQ-A4C6-01A-11R-A24Z-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.730
- INTERFERON_GAMMA_RESPONSE+0.600
- MYOGENESIS+0.390
- TNFA_SIGNALING_VIA_NFKB+0.380
- INFLAMMATORY_RESPONSE+0.370
- IL6_JAK_STAT3_SIGNALING+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- HYPOXIA+0.310
- ALLOGRAFT_REJECTION+0.280
- HEDGEHOG_SIGNALING+0.260
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.280
- ADIPOGENESIS-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.120
- WNT_BETA_CATENIN_SIGNALING-0.120
- PEROXISOME-0.090
- SPERMATOGENESIS-0.080
- ESTROGEN_RESPONSE_EARLY-0.070
- BILE_ACID_METABOLISM-0.060
- E2F_TARGETS-0.040
- XENOBIOTIC_METABOLISM-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6952-01A-11R-1915-07 | — | — | 0.875 |
| 2 | 270a14bb-8ae5-4372-a66b-b3d71bf217f7 | — | — | 0.837 |
| 3 | MDT-AP-3379 | Med | Medulloblastoma | 0.833 |
| 4 | R409 | — | — | 0.832 |
| 5 | SRR1516052 | — | — | 0.826 |
| 6 | SRR35579823 | — | D | 0.824 |
| 7 | TCGA-FT-A61P-01A-11R-A30C-07 | — | — | 0.817 |
| 8 | BS_06AMMCXR | low-grade glioma | — | 0.816 |
| 9 | ERR2208954 | — | — | 0.816 |
| 10 | R303 | — | — | 0.810 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.730 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |